1. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo–Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
- Author
-
Deodhar, Atul, Poddubnyy, Deni, Pacheco-Tena, Cesar, Salvarani, Carlo, Lespessailles, Eric, Rahman, Proton, Järvinen, Pentti, Sanchez-Burson, Juan, Gaffney, Karl, Lee, Eun Bong, Krishnan, Eswar, Santisteban, Silvia, Li, Xiaoqi, Zhao, Fangyi, Carlier, Hilde, Reveille, John D., Antolini, Christopher, Azevedo, Valderilio, Barkham, Magnu, Rodriguez, Aaron Alejandro Barrera, Berman, Alberto, Blicharski, Tomasz, Brzezicki, Jan, Burmester, Gerd, Carrio, Judith, Collantes, Eduardo, Combe, Bernard, Cons-Molina, Fidencio, Cortes-Maisonet, Gregorio, Dudek, Anna, Barragan, Sergio Duran, Elkayam, Ori, Flint, Kathleen, Galeazzi, Mauro, Gaylis, Norman, Goddard, David, Fernandez, Carlos Gonzalez, Goupille, Philippe, Masmitja, Jordi Grataco, Greenwald, Maria, Gremese, Elisa, Hong, Seung Jae, Howell, Mary, Hrycaj, Pawel, Ince, Akgun, Ju, Ji Hyeon, Kaine, Jeffrey, Kang, Seong Wook, Keiserman, Mauro, Kim, Tae-Hwan, Kivitz, Alan, Klein, Steven, Kremer, Joel, Lee, Sang Heon, Lee, Chang Keun, Lee, Sang-Hoon, Lidman, Roger, Loveless, Jame, Lucero, Eleonora, Cocco, Jose Maldonado, Marcolino, Flora, Mariette, Xavier, Mehta, Daksha, Morin, Frederic, Moscovici, Yolanda, Mueller, Eric, Mysler, Eduardo, Blasco, Francisco Navarro, Nguyen, Minh, Pantojas, Carlo, Park, Min-Chan, Jesus, Amarilis Perez-De, Peters, Eric, Plebanski, Rafal, Querubin, Roel, Remus, Cesar Ramo, Reitblat, Tatiana, Rivera, Tania, Rodriguez, Juan Cruz Rizo, Sayers, Michael, Scotton, Antonio, Scoville, Craig, Shaw, David, Shin, Kichul, Singhal, Atul, Skinner, Cassandra, Soto-Raices, Oscar, Soubrier, Martin, Szymanska, Malgorzata, Thai, Christine, van de Sande, Marleen, Wells, Alvin, Wojciechowski, Rafal, Xavier, Ricardo, Ximenes, Antonio, Zisman, Devy, Gremese, Elisa (ORCID:0000-0002-2248-1058), Deodhar, Atul, Poddubnyy, Deni, Pacheco-Tena, Cesar, Salvarani, Carlo, Lespessailles, Eric, Rahman, Proton, Järvinen, Pentti, Sanchez-Burson, Juan, Gaffney, Karl, Lee, Eun Bong, Krishnan, Eswar, Santisteban, Silvia, Li, Xiaoqi, Zhao, Fangyi, Carlier, Hilde, Reveille, John D., Antolini, Christopher, Azevedo, Valderilio, Barkham, Magnu, Rodriguez, Aaron Alejandro Barrera, Berman, Alberto, Blicharski, Tomasz, Brzezicki, Jan, Burmester, Gerd, Carrio, Judith, Collantes, Eduardo, Combe, Bernard, Cons-Molina, Fidencio, Cortes-Maisonet, Gregorio, Dudek, Anna, Barragan, Sergio Duran, Elkayam, Ori, Flint, Kathleen, Galeazzi, Mauro, Gaylis, Norman, Goddard, David, Fernandez, Carlos Gonzalez, Goupille, Philippe, Masmitja, Jordi Grataco, Greenwald, Maria, Gremese, Elisa, Hong, Seung Jae, Howell, Mary, Hrycaj, Pawel, Ince, Akgun, Ju, Ji Hyeon, Kaine, Jeffrey, Kang, Seong Wook, Keiserman, Mauro, Kim, Tae-Hwan, Kivitz, Alan, Klein, Steven, Kremer, Joel, Lee, Sang Heon, Lee, Chang Keun, Lee, Sang-Hoon, Lidman, Roger, Loveless, Jame, Lucero, Eleonora, Cocco, Jose Maldonado, Marcolino, Flora, Mariette, Xavier, Mehta, Daksha, Morin, Frederic, Moscovici, Yolanda, Mueller, Eric, Mysler, Eduardo, Blasco, Francisco Navarro, Nguyen, Minh, Pantojas, Carlo, Park, Min-Chan, Jesus, Amarilis Perez-De, Peters, Eric, Plebanski, Rafal, Querubin, Roel, Remus, Cesar Ramo, Reitblat, Tatiana, Rivera, Tania, Rodriguez, Juan Cruz Rizo, Sayers, Michael, Scotton, Antonio, Scoville, Craig, Shaw, David, Shin, Kichul, Singhal, Atul, Skinner, Cassandra, Soto-Raices, Oscar, Soubrier, Martin, Szymanska, Malgorzata, Thai, Christine, van de Sande, Marleen, Wells, Alvin, Wojciechowski, Rafal, Xavier, Ricardo, Ximenes, Antonio, Zisman, Devy, and Gremese, Elisa (ORCID:0000-0002-2248-1058)
- Abstract
Objective: To investigate the efficacy and safety of ixekizumab in patients with active radiographic axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 tumor necrosis factor inhibitors (TNFi). Methods: In this phase III randomized, double-blind, placebo-controlled trial, adult patients with an inadequate response to or intolerance of 1 or 2 TNFi and an established diagnosis of axial SpA (according to the Assessment of SpondyloArthritis international Society [ASAS] criteria for radiographic axial SpA, with radiographic sacroiliitis defined according to the modified New York criteria and ≥1 feature of SpA) were recruited and randomized 1:1:1 to receive placebo or 80-mg subcutaneous ixekizumab every 2 weeks (IXEQ2W) or 4 weeks (IXEQ4W), with an 80-mg or 160-mg starting dose. The primary end point was 40% improvement in disease activity according to the ASAS criteria (ASAS40) at week 16. Secondary outcomes and safety were also assessed. Results: A total of 316 patients were randomized to receive placebo (n = 104), IXEQ2W (n = 98), or IXEQ4W (n = 114). At week 16, significantly higher proportions of IXEQ2W patients (n = 30 [30.6%]; P = 0.003) or IXEQ4W patients (n = 29 [25.4%]; P = 0.017) had achieved an ASAS40 response versus the placebo group (n = 13 [12.5%]), with statistically significant differences reported as early as week 1 with ixekizumab treatment. Statistically significant improvements in disease activity, function, quality of life, and spinal magnetic resonance imaging–evident inflammation were observed after 16 weeks of ixekizumab treatment versus placebo. Treatment-emergent adverse events (AEs) with ixekizumab treatment were more frequent than with placebo. Serious AEs were similar across treatment arms. One death was reported (IXEQ2W group). Conclusion: Ixekizumab treatment for 16 weeks in patients with active radiographic axial SpA and previous inadequate response to or intolerance of 1 or 2 TNFi yields rapid and signi
- Published
- 2019